德勤-2020年全球生命科学展望（英文）-2020.3-64页_3mb

Summary of Deloitte 2020 Global Life Sciences Outlook

Core Content

The Deloitte 2020 Global Life Sciences Outlook outlines the evolving landscape of the life sciences sector, emphasizing the need for innovation, inclusivity, and a focus on the human experience in the face of rapid technological advancements. The report highlights how biopharma and medtech organizations can create new value through data-driven approaches, meaningful work, and strategic partnerships.

Main Viewpoints

1. Creating New Value

• Data-Driven Insights: The use of AI and machine learning is expected to transform therapy discovery and development, making them more innovative and cost-effective.
• Human-Centric Models: Patient-centric models are not only improving care but also influencing operational strategies and setting the foundation for personalized health care.
• Role of Humans in Technology: Despite automation, human expertise is still crucial in interpreting and curating unstructured data, such as in clinical notes and pathology reports.

2. Measuring the Human Experience

• Holistic Approach: Organizations should measure the human experience across all stakeholders—employees, patients, and ecosystem partners—to improve business outcomes.
• Collaboration Across Departments: Marketing, HR, operations, and IT leaders should break down silos and work together to create a unified set of experience measures.
• Customer-Centric Solutions: By mapping touchpoints and understanding patient needs, companies can design more empathetic and effective care solutions.

3. Inclusive Clinical Trials

• Importance of Diversity: Inclusive clinical trials are essential to ensure research findings are generalizable and applicable to all patient populations.
• Challenges in Inclusion: Racial and ethnic minorities, women, and the elderly are often underrepresented in clinical trials, leading to potential biases in treatment outcomes.
• Government Initiatives: Agencies like the NIH and NIA are working to increase inclusivity through initiatives like "All of Us" and the ROAR toolkit.
• Virtual Trials: Telemedicine and virtual trials can help overcome structural and clinical barriers to participation, increasing access and diversity.

4. Creating Value Through Meaningful Work

• Shift to Purpose-Driven Work: The future of work is moving towards meaningful and purpose-driven roles, with a focus on human capabilities rather than just skills.
• Employee Loyalty: Millennials and Gen Z are more likely to be loyal to employers that take meaningful action on issues like sustainability and social responsibility.
• Reverse Mentoring: Companies like Novartis are engaging in reverse mentoring to better understand and meet the needs of younger generations.

5. Market Trends and Deal Activity

• M&A Activity: 2019 saw a significant increase in deal values, with life sciences M&A reaching over $181.7 billion for the first three quarters.
• Biotech IPOs: 2019 witnessed a strong run of biotech IPOs with companies valuing over $2 billion, indicating continued investor confidence.
• Private Valuations: There has been a notable increase in private valuations, but the stock market volatility may lead to more realistic valuations in 2020.

6. Technology Acquisitions and Trends

• Software Dominance: Life sciences companies are increasingly acquiring software firms to enhance their capabilities in drug discovery, real-world evidence, and data management.
• Notable Deals: Major acquisitions like Dassault Systèmes buying Medidata Solutions and Thermo Fisher Scientific acquiring HighChem highlight the strategic importance of technology in the sector.
• Health Tech Unicorns: The rise of health-based technology unicorns (companies valued over $1 billion) shows the growing interest in innovative health solutions.

7. Cloud Investments

• Top Priority: Cloud technology is becoming a top priority for life sciences organizations due to its role in data modernization and security.
• Migration Trends: Over 85% of surveyed life sciences and health care companies have implemented or fully adopted data modernization.
• ERP and SAP: More enterprise resource planning (ERP) buyers are expected to move to the cloud in 2020, with SAP solutions being increasingly adopted for flexibility and scalability.

8. Return on Capital

• Declining ROC: Return on capital (ROC) has declined for various segments in the life sciences industry, prompting a shift in focus towards more efficient capital allocation.
• New Metrics: ROC is emerging as a key metric for 2020, offering insights into the efficiency of capital use and profitability.

Key Information

• Flatiron Health is a notable example of a company that successfully combined human expertise and technology to enhance cancer research and was acquired by Roche for $1.9 billion.
• HeLa Cells: These cells, derived from Henrietta Lacks, have been pivotal in medical research, yet their use raises ethical questions about patient consent and inclusivity.
• Teal Organizations: Organizations like Heiligenfeld are moving toward self-management and a deeper sense of purpose, fostering innovation and employee engagement.
• Direct Listings: The NYSE's introduction of direct listings as an alternative to IPOs is gaining traction, especially for technology-driven companies.

Conclusion

The life sciences sector is at a pivotal moment, driven by technological innovation, a focus on human experience, and the push for inclusivity in clinical research. Companies that adapt to these trends by investing in technology, fostering meaningful work, and ensuring diverse representation in trials are likely to gain a competitive advantage and deliver greater value to all stakeholders.